Håkan Mellstedt

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

Anders Österborg, Martin J.S. Dyer, Donald Bunjes et al. · Journal of Clinical Oncology · 1997 · 517 citations

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

Jeanette Lundin, Eva Kimby, Magnus Björkholm et al. · Blood · 2002 · 496 citations · Full text

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials

Stefano Pasquali, J D Maqueo, Jorge Espino Vela et al. · Oxford University Research Archive (ORA) (University of Oxford) · 1998 · 473 citations

Hematological Malignancy, Oncology, Metronomic Therapy +6

Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma.

Hiroshi Nakagomi, Max Petersson, I Magnusson et al. · PubMed · 1993 · 344 citations

Immunology, Immune Regulation, Pathology +19

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

Jeanette Lundin, Anders Österborg, G. Brittinger et al. · Journal of Clinical Oncology · 1998 · 258 citations